Skip to Content

'
Nicholas E. Papadopoulos, M.D.

Present Title & Affiliation

Primary Appointment

Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Boulevard,
Unit Number: 430
Houston,, TX 77030
Phone: 713 792-2921
Fax: 713 745-1046

Education & Training

Degree-Granting Education

1966 University of Athens, Athens, Greece, MD, Medicine

Postgraduate Training

1976-1978 Fellow in Medicine, Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
1974-1976 Residency, Medicine, Baylor College of Medicine, Houston, TX

Selected Publications

Peer-Reviewed Original Research Articles

1. Kolandjian NA, Wei C, Patel SP, Richard JL, Dett T, Papadopoulos NE, Bedikian AY. Delayed Systemic Recurrence of Uveal Melanoma. Am J Clin Oncol 36(5):443-9, 10/2013. e-Pub 6/14/2012. PMID: 22706174.
2. Patel SP, Lazar AJ, Papadopoulos NE, Liu P, Infante JR, Glass MR, Vaughn CS, LoRusso PM, Cohen RB, Davies MA, Kim KB. Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma. Cancer 119(4):799-805, 2/15/2013. e-Pub 9/12/2012. PMID: 22972589.
3. Radvanyi LG, Bernatchez C, Zhang M, Fox P, Miller P, Chacon J, Wu RC, Lizee G, Mahoney S, Alvarado G, Glass M, Johnson V, McMannis JD, Shpall EJ, Prieto VG, Papadopoulos NE, Kim KB, Homsi J, Bedikian AY, Hwu WJ, Patel S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Davies MA, Mansaray R, Fulbright OJ, Toth C, Ramachandran R, Wardell S, Gonzalez A, Hwu P. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res. e-Pub 10/2/2012. PMID: 23032743.
4. Noor R, Bedikian AY, Mahoney S, Bassett R, Kim K, Papadopoulos N, Hwu WJ, Hwu P, Homsi J. Comparison of two dosing schedules of palonosetron for the prevention of nausea and vomiting due to interleukin-2-based biochemotherapy. Support Care Cancer 20(10):2583-8, 10/2012. e-Pub 1/25/2012. PMID: 22274951.
5. Kim J, Lazar AJ, Davies MA, Homsi J, Papadopoulos NE, Hwu WJ, Bedikian AY, Woodman SE, Patel SP, Hwu P, Kim KB. BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma. J Cutan Pathol:821-5, 9/2012. e-Pub 7/19/2012. PMID: 22809251.
6. Kim KB, Prieto V, Joseph RW, Diwan AH, Gallick GE, Papadopoulos NE, Bedikian AY, Camacho LH, Hwu P, Ng CS, Wei W, Johnson MM, Wittemer SM, Vardeleon A, Reckeweg A, Colevas AD. A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma. Melanoma Res 22(4):294-301, 8/2012. e-Pub 6/2/2012. PMID: 22668797.
7. Alvarado G, Noor R, Bassett R, Papadopoulos NE, Kim KB, Hwu WJ, Bedikian A, Patel S, Hwu P, Davies MA. Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases. Melanoma Res 22(4):310-5, 8/2012. e-Pub 5/2012. PMID: 22584956.
8. Davies MA, Fox PS, Papadopoulos NE, Bedikian AY, Hwu WJ, Lazar AJ, Prieto VG, Culotta KS, Madden TL, Xu Q, Huang S, Deng W, Ng C, Gupta S, Liu W, Dancey JE, Wright JJ, Bassett RL, Hwu P, Kim KB. Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. Clin Cancer Res. e-Pub 1/5/2012. PMID: 22223528.
9. Patel SP, Kim KB, Papadopoulos NE, Hwu WJ, Hwu P, Prieto VG, Bar-Eli M, Zigler M, Dobroff A, Bronstein Y, Bassett RL, Vardeleon AG, Bedikian AY. A phase II study of gefitinib in patients with metastatic melanoma. Melanoma Res 21(4):357-63, 8/2011. PMCID: PMC3132394.
10. Bedikian AY, Silverman JA, Papadopoulos NE, Kim KB, Hagey AE, Vardeleon A, Hwu WJ, Homsi J, Davies M, Hwu P. Pharmacokinetics and safety of marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver function. J Clin Pharmacol 51(8):1205-12, 8/2011. e-Pub 10/26/2010. PMID: 20978276.
11. Joseph RW, Peddareddigari VR, Liu P, Miller P, Overwijk W, Bekele BN, Ross MI, Lee JS, Gershenwald JE, Lucci A, Prieto VG, McMannis JD, Papadopoulos N, Kim KB, Homsi J, Bedikian AY, Hwu WJ, Hwu P, Radvanyi L. Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy. Clin Cancer Res. e-Pub 6/6/2011. PMID: 21632855.
12. Kolandjian NA, Patel SP, Papadopoulos NE, Bedikian AY. The left ventricle as the first site of uveal melanoma metastasis 13 years after treatment of the primary tumor. Melanoma Res. e-Pub 2/19/2011. PMID: 21346640.
13. Alvarado GC, Papadopoulos NE, Hwu WJ, Bedikian AY, Homsi J, Myers JN, Bronstein Y, Bassett RL, Hwu P, Kim KB. Pelvic computed tomography scans for surveillance in patients with primary melanoma in the head and neck. Melanoma Res. e-Pub 12/16/2010. PMID: 21169870.
14. Bedikian AY, Wei C, Detry M, Kim KB, Papadopoulos NE, Hwu WJ, Homsi J, Davies M, McIntyre S, Hwu P. Predictive Factors for the Development of Brain Metastasis in Advanced Unresectable Metastatic Melanoma. Am J Clin Oncol - Canc. e-Pub 12/2010. PMID: 21150567.
15. Bedikian AY, Johnson MM, Warneke CL, Papadopoulos NE, Kim KB, Hwu WJ, McIntyre S, Rohlfs M, Homsi J, Hwu P. Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival? Melanoma Res. e-Pub 11/22/2010. PMID: 21102360.
16. Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, Hwu P, Bedikian A. Prognostic factors for survival in melanoma patients with brain metastases. Cancer - Am Cancer Soc. e-Pub 10/2010. PMID: 20960525.
17. Hwu WJ, Knight RD, Patnana M, Bassett R, Papadopoulos NE, Kim KB, Hwu P, Bedikian A. Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapy. Melanoma Res. e-Pub 9/20/2010. PMID: 20859231.
18. Homsi J, Bedikian AY, Papadopoulos NE, Kim KB, Hwu WJ, Mahoney SL, Hwu P. Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma. Melanoma Res. e-Pub 9/2010. PMID: 20881508.
19. Bedikian AY, DeConti RC, Conry R, Agarwala S, Papadopoulos N, Kim KB, Ernstoff M. Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma. Ann Oncol. e-Pub 9/2010. PMID: 20855467.
20. Yoon C, Papadopoulos NE, Camocho LH, McIntyre S, Alvarado GC, Bedkian AY, Hwu P, Kim KB. The Clinical Efficacy of Combination of Docetaxel and Temozolomide in Previously Treated Patients with Stage IV Melanoma. Melanoma Res 20(1):43-47, 2/2010. PMID: 19952963.
21. Eton O, Ross MI, East MJ, Mansfield PF, Papadopoulos N, Ellerhorst JA, Bedikian AY, Lee JE. Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96)in patients with metastatic melanoma. J Transl Med 8(1):9, 1/2010. PMID: 20109236.
22. Bedikian AY, Papadopoulos NE, Kim KB, Hwu WJ, Homsi J, Glass MR, Cain S, Rudewicz P, Vernillet L, Hwu P. A Phase IB Trial of Intravenous INO-1001 Plus Oral Temozolomide in Subjects with Unresectable Stage-III or IV Melanoma. Cancer Invest 27(7):756-63, 8/2009. PMID: 19440934.
23. Woodman SE, Trent JC, Stemke-Hale K, Lazar AJ, Pricl S, Pavan GM, Fermeglia M, Gopal YN, Yang D, Podoloff DA, Ivan D, Kim KB, Papadopoulos N, Hwu P, Mills GB, Davies MA. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther 8(8). e-Pub 8/2009. PMID: 19671763.
24. Homsi J, Bedikian AY, Kim KB, Papadopoulos NE, Hwu WJ, Mahoney SL, Hwu P. Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients. Melanoma Res 19(4):238-42, 8/2009. PMID: 19521262.
25. Kim KB, Hwu WJ, Papadopoulos NE, Bedikian AY, Camacho LH, Ng C, Hernandez IM, Frost AM, Jack MA, Hwu P. Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma. Cancer Chemoth Pharm 64(1):167-7, 6/2009. e-Pub 11/2008. PMID: 19002462.
26. Papadopoulos NE, Bedikian A, Ring S, Kim KB, Hwu WJ, Gerber DL, Homsi J, Hwu P. Phase I/II Study of a Cisplatin-Taxol-Dacarbazine Regimen in Metastatic Melanoma. Am J Clin Oncol - Canc. e-Pub 6/2009. PMID: 19506454.
27. Akhtari M, Waller EK, Jaye DL, Lawson DH, Ibrahim R, Papadopoulos NE, Arellano ML. Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody). J Immunother 32(3):322-4, 4/2009. PMID: 19242368.
28. Kim KB, Legha SS, Gonzalez R, Anderson CM, Johnson MM, Liu P, Papadopoulos NE, Eton O, Plager C, Buzaid AC, Prieto VG, Hwu WJ, Frost AM, Alvarado G, Hwu P, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Benjamin RS, Bedikian AY. A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Res 19(1):42-9, 2/2009. PMID: 19430405.
29. Bedikian AY, Papadopoulos NE, Kim KB, Vardeleon A, Smith T, Lu B, Deitcher SR. A pilot study with vincristine sulfate liposome infusion in patients with metastatic melanoma. Melanoma Res 18(6):400-4, 12/2008. PMID: 19011511.
30. Bartell HL, Bedikian AY, Papadopoulos NE, Dett TK, Ballo MT, Myers JN, Hwu P, Kim KB. Biochemotherapy in patients with advanced head and neck mucosal melanoma. Head Neck 30(12):1592-8, 12/2008. PMID: 18798304.
31. Kim KB, Eton O, Davis DW, Frazier ML, McConkey DJ, Diwan AH, Papadopoulos NE, Bedikian AY, Camacho LH, Ross MI, Cormier JN, Gershenwald JE, Lee JE, Mansfield PF, Billings LA, Ng CS, Charnsangavej C, Bar-Eli M, Johnson MM, Murgo AJ, Prieto VG. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Brit J Cancer 99(5). e-Pub 8/2008. PMID: 18728664.
32. Bedikian AY, Johnson MM, Warneke CL, Papadopoulos NE, Kim K, Hwu WJ, McIntyre S, Hwu P. Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Cancer Invest 26(6):624-33, 7/2008. PMID: 18584354.
33. Wang C, Bedikian AY, Papadopoulos NE, Kim KB, Hwu P. Restrospective Com0parison of Outcomes in Patients Receiving Systemic Therapies for Unresectable Metastatic Melanoma of Unknown Primary Site and Metastatic Cutaneous Melanoma. Cancer Ther 6(2):895-901, 2008.
34. Kim KB, Eton O, East MJ, Hodges C, Papadopoulos NE, Grimm EA, Bedikian AY. Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma. Cancer 101:596-603, 8/2004. PMID: 15274073.
35. Kim KB, Sanguino AM, Hodges C, Papadopoulos NE, Eton O, Camacho LH, Broemeling LD, Johnson MM, Ballo MT, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Prieto VG, Bedikian AY. Biochemotherapy in patients with metastatic anorectal mucosal melanoma. Cancer 100:1478-83, 4/2004. PMID: 15042682.
36. Bedikian AY, Plager C, Papadopoulos N, Eton O, Ellerhorst J, Smith T. Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma. Melanoma Res 14:63-6, 2/2004. PMID: 15091196.
37. Trent JC, Beach J, Burgess MA, Papadopolous N, Chen LL, Benjamin RS, Patel SR. A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer 98:2693-9, 12/2003. PMID: 14669291.
38. Vadhan-Raj S, Patel S, Bueso-Ramos C, Folloder J, Papadopolous N, Burgess A, Broemeling LD, Broxmeyer HE, Benjamin RS. Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia. J Clin Oncol 21:3158-67, 8/2003. PMID: 12915607.
39. Bedikian AY, Papadopoulos N, Plager C, Eton O, Ring S. Phase II evaluation of temozolomide in metastatic choroidal melanoma. Melanoma Res 13:303-6, 6/2003. PMID: 12777987.
40. Patel SR, Beach J, Papadopoulos N, Burgess MA, Trent J, Jenkins J, Benjamin RS. Results of a 2-arm Phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas. Cancer 97:2848-52, 6/2003. PMID: 12767099.

Abstracts

1. Kim, KB, Hodges C, Papadopoulos N, Eton O, Camacho LH, Ballo MT, Bedikian AY. Biochemotherapy in patients with metastatic anorectal melanoma (MAM). . Proc. Am Soc Clin Oncol 22:718 (#2889), 2003.
2. Papadopoulos, N, Bedikian AY, Ring S, Kim KB, Camacho LH, Eton O. Phase II study of CTD (cisplatin, paclitaxel, DTIC) in metastatic melanoma (MM). . Proc. Am Soc Clin Oncol 22:718, 2003.

Last updated: 4/2/2014